The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Sezary Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Sezary Syndrome


High impact information on Sezary Syndrome


Chemical compound and disease context of Sezary Syndrome


Biological context of Sezary Syndrome


Anatomical context of Sezary Syndrome


Gene context of Sezary Syndrome


Analytical, diagnostic and therapeutic context of Sezary Syndrome


  1. Hodgkin's disease. An immunodepleting and immunosuppressive disorder. Twomey, J.J., Laughter, A.H., Farrow, S., Douglass, C.C. J. Clin. Invest. (1975) [Pubmed]
  2. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Kuzel, T.M., Hurria, A., Samuelson, E., Tallman, M.S., Roenigk, H.H., Rademaker, A.W., Rosen, S.T. Blood (1996) [Pubmed]
  3. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Winkler, C.F., Sausville, E.A., Ihde, D.C., Fischmann, A.B., Schechter, G.P., Kumar, P.P., Nibhanupdi, J.R., Minna, J.D., Makuch, R.W., Eddy, J.L. J. Clin. Oncol. (1986) [Pubmed]
  4. Human T-cell leukemia virus type I or a related retrovirus in patients with mycosis fungoides/Sézary syndrome and Kaposi's sarcoma. Srivastava, B.I., Banki, K., Perl, A. Cancer Res. (1992) [Pubmed]
  5. Abatement of Sézary syndrome lesions following treatment with acyclovir. Scheman, A.J., Steinberg, I., Taddeini, L. Am. J. Med. (1986) [Pubmed]
  6. Thymopentin in Sézary syndrome. Bernengo, M.G., Appino, A., Bertero, M., Novelli, M., Fierro, M.T., Doveil, G.C., Lisa, F. J. Natl. Cancer Inst. (1992) [Pubmed]
  7. Antilymphocyte globulin in the treatment of advanced Sézary syndrome. Barett, A.J., Staughton, R.C., Brigden, D., Byrom, N., Roberts, J.T., Hobbs, J.R. Lancet (1976) [Pubmed]
  8. Significance of circulating T-cell clones in Sezary syndrome. Ortonne, N., Huet, D., Gaudez, C., Marie-Cardine, A., Schiavon, V., Bagot, M., Musette, P., Bensussan, A. Blood (2006) [Pubmed]
  9. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L. French, L.E., Huard, B., Wysocka, M., Shane, R., Contassot, E., Arrighi, J.F., Piguet, V., Calderara, S., Rook, A.H. Blood (2005) [Pubmed]
  10. 2-Chlorodeoxyadenosine treatment in the Sezary syndrome. Zaucha, J.M., Lewandowski, K., Hellmann, A., Pawlik, H., Siedlewicz, A. Blood (1997) [Pubmed]
  11. Membrane receptors and their redistribution in lymphoproliferative disorders. Naeim, F., Bergmann, K., Gatti, R.A. Blood (1979) [Pubmed]
  12. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. Foss, F.M., Ihde, D.C., Linnoila, I.R., Fischmann, A.B., Schechter, G.P., Cotelingam, J.D., Steinberg, S.M., Ghosh, B.C., Stocker, J.L., Bastian, A. J. Clin. Oncol. (1994) [Pubmed]
  13. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. Zhang, C., Ni, X., Konopleva, M., Andreeff, M., Duvic, M. J. Invest. Dermatol. (2004) [Pubmed]
  14. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Mitchell, T.J., Whittaker, S.J., John, S. Cancer Res. (2003) [Pubmed]
  15. Application of a multiprobe RNase protection assay and junctional sequences to define V beta gene diversity in Sezary syndrome. Kono, D.H., Baccala, R., Balderas, R.S., Kovac, S.J., Heald, P.W., Edelson, R.L., Theofilopoulos, A.N. Am. J. Pathol. (1992) [Pubmed]
  16. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. Showe, L.C., Fox, F.E., Williams, D., Au, K., Niu, Z., Rook, A.H. J. Immunol. (1999) [Pubmed]
  17. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). Wood, G.S., Tung, R.M., Haeffner, A.C., Crooks, C.F., Liao, S., Orozco, R., Veelken, H., Kadin, M.E., Koh, H., Heald, P. J. Invest. Dermatol. (1994) [Pubmed]
  18. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. Scarisbrick, J.J., Woolford, A.J., Calonje, E., Photiou, A., Ferreira, S., Orchard, G., Russell-Jones, R., Whittaker, S.J. J. Invest. Dermatol. (2002) [Pubmed]
  19. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Brender, C., Nielsen, M., Kaltoft, K., Mikkelsen, G., Zhang, Q., Wasik, M., Billestrup, N., Odum, N. Blood (2001) [Pubmed]
  20. Triterpenoid electrophiles (avicins) suppress heat shock protein-70 and x-linked inhibitor of apoptosis proteins in malignant cells by activation of ubiquitin machinery: implications for proapoptotic activity. Gaikwad, A., Poblenz, A., Haridas, V., Zhang, C., Duvic, M., Gutterman, J. Clin. Cancer Res. (2005) [Pubmed]
  21. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. Vowels, B.R., Cassin, M., Vonderheid, E.C., Rook, A.H. J. Invest. Dermatol. (1992) [Pubmed]
  22. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. Seo, N., Tokura, Y., Matsumoto, K., Furukawa, F., Takigawa, M. Clin. Exp. Immunol. (1998) [Pubmed]
  23. Biological effects of bexarotene in cutaneous T-cell lymphoma. Budgin, J.B., Richardson, S.K., Newton, S.B., Wysocka, M., Zaki, M.H., Benoit, B., Rook, A.H. Archives of dermatology. (2005) [Pubmed]
  24. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Döbbeling, U., Dummer, R., Laine, E., Potoczna, N., Qin, J.Z., Burg, G. Blood (1998) [Pubmed]
  25. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Robey, R.W., Zhan, Z., Piekarz, R.L., Kayastha, G.L., Fojo, T., Bates, S.E. Clin. Cancer Res. (2006) [Pubmed]
  26. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Eriksen, K.W., Kaltoft, K., Mikkelsen, G., Nielsen, M., Zhang, Q., Geisler, C., Nissen, M.H., Röpke, C., Wasik, M.A., Odum, N. Leukemia (2001) [Pubmed]
  27. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Sokolowska-Wojdylo, M., Wenzel, J., Gaffal, E., Lenz, J., Speuser, P., Erdmann, S., Abuzahra, F., Bowman, E., Roszkiewicz, J., Bieber, T., Tüting, T. Br. J. Dermatol. (2005) [Pubmed]
  28. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Nickoloff, B.J., Fivenson, D.P., Kunkel, S.L., Strieter, R.M., Turka, L.A. Clin. Immunol. Immunopathol. (1994) [Pubmed]
  29. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. McGinnis, K.S., Ubriani, R., Newton, S., Junkins-Hopkins, J.M., Vittorio, C.C., Kim, E.J., Wysocka, M., Rook, A.H. Archives of dermatology. (2005) [Pubmed]
  30. Staging of Sezary syndrome with somatostatin receptor scintigraphy. Heule, F., Vanhagen, P.M., van Dongen, J.J., Krenning, E.P., Reubi, J.C., van Joost, T. Br. J. Dermatol. (1996) [Pubmed]
  31. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. Yoo, E.K., Cassin, M., Lessin, S.R., Rook, A.H. J. Am. Acad. Dermatol. (2001) [Pubmed]
  32. Long-term cytapheresis in the treatment of Sézary-syndrome. Müller, N., Lange, C.E. The International journal of artificial organs. (1984) [Pubmed]
WikiGenes - Universities